1865-3774 < 1865-8652 < 1866-0452

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by 1865-8652

Number of relevant bibliographic references: 14.

Ident.	Authors (with country if any)	Title
000585 (2020)	Zakir Khan [Pakistan] ; Yusuf Karata [Turquie] ; Hazir Rahman	Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action
000726 (2019)	Roberta Gualtierotti [Italie] ; Francesca Ingegnoli [Italie] ; Massimo Boscolo [Italie] ; Samantha Griffini [Italie] ; Elena Grovetti [Italie] ; Massimo Cugno [Italie]	Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
000A94 (2019)	Toby M. Maher [Royaume-Uni] ; Wim Wuyts [Belgique]	Management of Fibrosing Interstitial Lung Diseases
000B77 (2019)	Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France]	Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
000D49 (2019)	Noemi Muszbek [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Marie Fournier [France] ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Zsofia Kiss [Royaume-Uni] ; Peter Gal [Hongrie] ; Kaleb Michaud [États-Unis]	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
000E16 (2019)	Dipen Patel [États-Unis] ; Ahmed Shelbaya [États-Unis] ; Raymond Cheung [États-Unis] ; Jyoti Aggarwal [États-Unis] ; Sang Hee Park [États-Unis] ; Javier Coindreau [États-Unis]	Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
001392 (2018)	Paul Emery [Royaume-Uni] ; Janet E. Pope [Canada] ; Klaus Kruger [Allemagne] ; Ralph Lippe [Allemagne] ; Ryan Demasi [États-Unis] ; Sadiq Lula [Royaume-Uni] ; Blerina Kola [Royaume-Uni]	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.
001517 (2018)	Nikos Maniadakis [Grèce] ; Emese Toth [Belgique] ; Michael Schiff [États-Unis] ; Xuan Wang [Suède] ; Maria Nassim [Suède] ; Boglarka Szegvari [Belgique] ; Irina Mountian [Belgique] ; Jeffrey R. Curtis [États-Unis]	A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
001583 (2017)	Benjamin Chastek [États-Unis] ; Chieh-I Chen [États-Unis] ; Clare Proudfoot [Royaume-Uni] ; Shraddha Shinde [États-Unis] ; Andreas Kuznik [États-Unis] ; Wenhui Wei [États-Unis]	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
001584 (2017)	Wenhui Wei [États-Unis] ; Keith Knapp [États-Unis] ; Li Wang [États-Unis] ; Chieh-I Chen [États-Unis] ; Gary L. Craig [États-Unis] ; Karen Ferguson [États-Unis] ; Sergio Schwartzman [États-Unis]	Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
001B92 (2016)	Alberto Batticciotto [Italie] ; Roberto Ravasio [Italie] ; Marta Riva [Italie] ; Piercarlo Sarzi-Puttini [Italie]	Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.
001C89 (2016)	Benjamin Chastek [États-Unis] ; John White [États-Unis] ; Damon Van Voorhis [États-Unis] ; Derek Tang [États-Unis] ; Bradley S. Stolshek [États-Unis]	A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
003413 (2012)	Machaon Bonafede [États-Unis] ; Kathleen M. Fox ; Crystal Watson ; Nicole Princic ; Shravanthi R. Gandra	Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
003522 (2012)	Yifei Liu [États-Unis] ; Eric Q. Wu ; Arielle G. Bensimon ; Chun-Po Steve Fan ; Yanjun Bao ; Arijit Ganguli ; Mei Yang ; Mary Cifaldi ; Parvez Mulani	Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "1865-8652" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "1865-8652" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1865-8652
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021